Premium
BRENTUXIMAB VEDOTIN SALVAGE FOLLOWED BY CONSOLIDATION POST AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN HIGH RISK RELAPSED REFRACTORY HODGKIN LYMPHOMA
Author(s) -
Damlaj M.,
Alaskar A.,
Gmati G.,
Abuelgasim K.,
Alahmari B.,
Ghazi S.,
Alhejazi A.,
Alzahrani M.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.171_2631
Subject(s) - medicine , brentuximab vedotin , salvage therapy , oncology , refractory (planetary science) , clinical endpoint , hematopoietic stem cell transplantation , transplantation , chemoimmunotherapy , surgery , lymphoma , chemotherapy , cyclophosphamide , hodgkin lymphoma , clinical trial , astrobiology , physics
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom